Ranibizumab
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Ranibizumab?
Summarize this article for a 10 year old
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic[14] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Monoclonal antibody | |
---|---|
Type | Fab fragment |
Source | Humanized (from mouse) |
Target | Vascular endothelial growth factor A (VEGF-A) |
Clinical data | |
Trade names | Lucentis, others |
Biosimilars | Ranibizumab-nuna,[1] Ranibizumab-eqrn,[2] Byooviz,[1][3] Cimerli,[2] Ranivisio,[4] Raniviz,[5] Susvimo,[6] Ximluci[7] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607044 |
License data |
|
Pregnancy category | |
Routes of administration | Intravitreal injection |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | Approx. 9 days[12] |
Identifiers | |
CAS Number | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
Chemical and physical data | |
Formula | C2158H3282N562O681S12 |
Molar mass | 48379.97 g·mol−1 |
NY (what is this?) (verify) |
Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis,[15] under the brand name Lucentis.[12][15][16] Ranibizumab (Lucentis) was approved for medical use in the United States in June 2006,[16][12] and in the European Union in January 2007.